# In8bio

In8bio is an Asset Manager based in New York, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** New York, United States
- **Region:** North America
- **Address:** New York, NY, United States
- **Assets under management:** Undisclosed
- **Website:** in8bio.com
- **LinkedIn:** https://www.linkedin.com/company/in8bio

## Regulatory record

- **Reports private funds:** No

## About

In8bio was founded to commercialize gamma-delta T cell technology, a class of immune cells that bridge innate and adaptive immunity. William Ho serves as CEO, leading the company's pipeline of investigational cell therapies. The firm's wealth origin is not publicly disclosed, as it is a public company. The firm's strategy centers on allogeneic cell therapy, using donor-derived gamma-delta T cells engineered to target tumors. It has two lead investigational products: INB-200 for glioblastoma and INB-100 for hematologic malignancies. In8bio also develops a platform to enhance cell persistence and tumor trafficking. The geographic footprint is US-based, with clinical trial sites primarily in North America. As a public company, In8bio reports no standard AUM. It had approximately 58 employees as of its latest filings. The firm operates from its New York City headquarters. In December 2023, In8bio presented updated clinical data for INB-100 at the American Society of Hematology annual meeting (per public release, December 2023). In8bio's structural differentiator lies in its exclusive focus on gamma-delta T cells, a less crowded area of cell therapy compared to CAR-T. This niche approach allows the firm to target solid tumors and hematologic cancers with a potential off-the-shelf product, reducing manufacturing complexity.

## Sectors

- Biotech
- Healthcare Services
- Therapeutics

## People

- William Ho — CEO and Director

## Questions

### What is the core technology platform at In8bio?

In8bio focuses on gamma-delta T cells, a type of immune cell that can target tumors without requiring HLA matching. The firm develops both autologous and allogeneic therapies using this platform, aiming for off-the-shelf cell therapy products.

### Which clinical trials is In8bio currently running?

In8bio has two lead programs: INB-200 for newly diagnosed glioblastoma multiforme and INB-100 for patients with hematologic malignancies undergoing stem cell transplant. Both are in Phase 1 clinical trials in the United States.

### What is the investment stage for In8bio?

In8bio is a clinical-stage company, meaning its therapies are in human trials but not yet commercialized. It generates no product revenue and relies on equity financing, grants, and partnerships to fund operations.

## Related profiles

- [Nocopi Technologies](https://altss.com/profile/nocopi-technologies-incmd)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/in8bio-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology